Perthera, Inc., the leading cancer therapeutic intelligence company, announced that Gary L. Gregory has joined the company as its Chief Executive Officer, President and Board Member.
Mr. Gregory is an experienced CEO and Board Member with 30 years of progressively challenging responsibilities in the MedTech Sector. His experience spans numerous companies and positions, including Executive Officer roles across several successful start-up companies (Neuronix, Advanced Dx, NeuroMetrix, PrimeSource Healthcare), and leadership roles in Fortune 250 companies (Johnson & Johnson, Baxter, and Kendall Healthcare). Gary has also served in Board roles from Chairman to Director for numerous organizations. He is recognized as a proven executive leader with big company capabilities and a keen start-up mindset.
“After an extensive search, we are most enthused to have Gary to join us as the new CEO and leader of Perthera. Gary’s leadership and results in building several previous companies makes him a remarkable asset for Perthera. His experience, recognized capabilities and accomplished approach will be invaluable in advancing our mission to provide healthcare providers, physicians and patients with a best-in-class, precision cancer care solution,” reported Emanuel Petricoin, Perthera’s Chairman and Chief Science Officer.
“I am excited to lead Perthera, and advance the company’s impressive technology foundation, which has already been proven to dramatically advance patient care and outcomes in the precision cancer care arena. 10% of oncologists across the US have already used the Perthera service to advance their care of cancer patients. I look forward to forging a vision for Perthera, and working alongside my colleagues to deliver our highly innovative technology and service to healthcare organizations, physicians, payers and patients, as we create a new standard of care in precision cancer medicine,” stated Gary L. Gregory, Perthera’s CEO and President.
Of note, each of Mr. Gregory’s start-ups have posted significant market growth, and his achievements include executing a successful IPO, driving substantial revenue & earning multiples for a publicly traded company, marshalling medical technologies through positive M&A efforts, and generating $50M+ in corporate financing efforts. “The markets developed, performances delivered, and people and patients Gary has impacted stand as a hallmark of his career. His vision and proven record in building clinically focused, technology powered companies uniquely positions Gary to build Perthera into a market leading company in the expansive, precision medicine arena,” added Dr. Petricoin.